Clinical Trial Update: Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating adjuvant 177Lu-DOTATATE versus best supportive care after surgical resection of neuroendocrine liver metastases; the study status is te…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroenteropancreatic Neuroendocrine Tumor
• Neuroendocrine Tumor

Drugs mentioned

• 177Lu-DOTATATE (Lutetium-177 dotatate)

Snippet

Sponsor: Imperial College London | Conditions: Neuroendocrine Tumor G1 (NET G1)/Carcinoid, Neuroendocrine Tumor Grade 2 | Phase 2 | Status: TERMINATED